WEDNESDAY, Feb. 26, 2025 (HealthDay News) -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...

Phase I Tiffany-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-T02 as a monotherapy in patients with advanced solid tumors COPENHAGEN, Denmark, Feb. 26 ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

A Yale University study explores the newly defined post-vaccination syndrome (PVS), revealing alarming biological changes among affected individuals and potential paths for diagnosis and treatment.